- Thursday, March 30, 2023
8:30 AM – 8:45 AM CT
Welcome
8:30 AM – 8:45 AM CT
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### 8:45 AM – 9:00 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
8:45 AM – 9:00 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 9:00 AM – 9:15 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
9:00 AM – 9:15 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant ImmunotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor ###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 9:15 AM – 9:30 AM CT
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Discussion
9:15 AM – 9:30 AM CT
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor ###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 9:30 AM – 10:30 AM CT
Treatment Options for Certain Patients With Select Advanced Upper Gastrointestinal Cancers. Speaker: John Berry, MD
9:30 AM – 10:30 AM CT
Non-CME Innovation Theater (Sponsored by Merck)
10:30 AM – 10:45 AM CT
Exhibit Hall
10:30 AM – 10:45 AM CT
Exhibit Hall
10:45 AM – 11:00 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
10:45 AM – 11:00 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 11:00 AM – 11:15 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
11:00 AM – 11:15 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - ChemotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor ###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 11:15 AM – 11:30 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DISCUSSION
11:15 AM – 11:30 AM CT
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DiscussionSession Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Kansas University Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Session Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Session Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Anup Kasi, MD MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor ###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### 11:30 AM – 12:15 PM CT
Session 3: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing
11:30 AM – 12:15 PM CT
Session 3: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment StrategiesPresenter: – University of Wisconsin, Carbone Cancer Center
Nataliya Uboha, MD, PhD – University of Wisconsin, Carbone Cancer Center ### 904441###Presenter###Associate Professor###University of Wisconsin, Carbone Cancer Center###Presenter: – University of Wisconsin, Carbone Cancer Center
### 12:15 PM – 1:15 PM CT
Evolving Biomarker Landscape in Gastric and Gastroesophageal Junction Adenocarcinomas. Speaker: Stephanie Braun
12:15 PM – 1:15 PM CT
Non-CME Innovation Theater (Sponsored by Astellas)
1:15 PM – 2:00 PM CT
Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal Malignancies
1:15 PM – 2:00 PM CT
Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal MalignanciesPresenter: – Department of Hematology and Oncology at Cleveland Clinic
Suneel Kamath, MD (he/him/his) – Department of Hematology and Oncology at Cleveland Clinic ### 1886496###Presenter###Assistant Professor of Medicine###Department of Hematology and Oncology at Cleveland Clinic###Presenter: – Department of Hematology and Oncology at Cleveland Clinic
### he/him/his2:00 PM – 2:45 PM CT
6 - Session 5: Integration of Supportive Care
2:00 PM – 2:45 PM CT
Session 5: Integration of Supportive CarePresenter: –
Memorial Sloan Kettering Cancer Center
Andrew Epstein, MD –
Memorial Sloan Kettering Cancer Center ### 1880690###Presenter###Associate Attending ###
Memorial Sloan Kettering Cancer Center###Presenter: –
Memorial Sloan Kettering Cancer Center
### 2:45 PM – 3:15 PM CT
Exhibit Hall
2:45 PM – 3:15 PM CT
Exhibit Hall
3:15 PM – 4:00 PM CT
7 - Session 6: Perspectives on Clinical Trial Development in Anal Cancer
3:15 PM – 4:00 PM CT
Session 6: Perspectives on Clinical Trial Development in Anal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
###
